Literature DB >> 18997223

Evidence-based decision making: when should we wait for more information?

Kalipso Chalkidou1, Joanne Lord, Alastair Fischer, Peter Littlejohns.   

Abstract

We discuss the challenge of managing innovation in and access to health care interventions in an evidence-based, cost-effective way, and we describe a decision-making framework (using U.S. and U.K. case studies) for health care payers considering the adoption of new technologies. We argue that providing reimbursement for what could be a cost-effective technology "only in the context of research" will be appropriate if the costs of delaying implementation are offset by the value of "keeping one's options open" by waiting for more information. We conclude that there is a need for better integration of health care decision-making processes with research policies.

Mesh:

Year:  2008        PMID: 18997223     DOI: 10.1377/hlthaff.27.6.1642

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  23 in total

1.  Value-based purchasing of medical devices.

Authors:  William T Obremskey; Teresa Dail; A Alex Jahangir
Journal:  Clin Orthop Relat Res       Date:  2012-04       Impact factor: 4.176

2.  When to wait for more evidence? Real options analysis in proton therapy.

Authors:  Janneke P C Grutters; Keith R Abrams; Dirk de Ruysscher; Madelon Pijls-Johannesma; Hans J M Peters; Eric Beutner; Philippe Lambin; Manuela A Joore
Journal:  Oncologist       Date:  2011-12-06

Review 3.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

5.  Examining the role of carbon capture and storage through an ethical lens.

Authors:  Fabien Medvecky; Justine Lacey; Peta Ashworth
Journal:  Sci Eng Ethics       Date:  2013-09-24       Impact factor: 3.525

6.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Comparative effectiveness research and evidence-based health policy: experience from four countries.

Authors:  Kalipso Chalkidou; Sean Tunis; Ruth Lopert; Lise Rochaix; Peter T Sawicki; Mona Nasser; Bertrand Xerri
Journal:  Milbank Q       Date:  2009-06       Impact factor: 4.911

9.  Expensive cancer drugs: a comparison between the United States and the United Kingdom.

Authors:  Ruth R Faden; Kalipso Chalkidou; John Appleby; Hugh R Waters; Jonathon P Leider
Journal:  Milbank Q       Date:  2009-12       Impact factor: 4.911

Review 10.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.